Edge Rewrite
everything Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a22b78b33eac4bc2

Jump to content

// Workers AI · dad joke modeWhy Nebracetam? Brain it on.

From Wikipedia, the free encyclopedia

Nebracetam
Clinical data
ATC code
  • none
Legal status
Legal status
  • AU: S4 (Prescription only)
  • US: Unscheduled Not FDA approved
Identifiers
  • (RS)-4-(Aminomethyl)-1-benzylpyrrolidin-2-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H16N2O
Molar mass204.273 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • O=C2N(Cc1ccccc1)CC(C2)CN
  • InChI=1S/C12H16N2O/c13-7-11-6-12(15)14(9-11)8-10-4-2-1-3-5-10/h1-5,11H,6-9,13H2 checkY
  • Key:LCAFGJGYCUMTGS-UHFFFAOYSA-N checkY
 X markNcheckY (what is this?)  (verify)

Nebracetam is an investigational drug of the racetam family that is a M1 acetylcholine receptor agonist in rats.[1] Based on a human leukemic T cell experiment in 1991, it is believed to act as an agonist for human M1-muscarinic receptors.[2] It is also believed to act as a nootropic, like many other racetam drugs.[3] A chemoenzymatic method of synthesis was reported in 2008.[4] As of 2023, human trials have not yet been conducted.

See also

[edit]

References

[edit]
  1. ↑ Takeo S, Hayashi H, Miyake K, Takagi K, Tadokoro M, Takagi N, et al. (June 1997). "Effects of delayed treatment with nebracetam on neurotransmitters in brain regions after microsphere embolism in rats". British Journal of Pharmacology. 121 (3): 477–484. doi:10.1038/sj.bjp.0701161. PMC 1564714. PMID 9179389.
  2. ↑ Kitamura Y, Kaneda T, Nomura Y (January 1991). "Effects of nebracetam (WEB 1881 FU), a novel nootropic, as a M1-muscarinic agonist". Japanese Journal of Pharmacology. 55 (1): 177–180. doi:10.1254/jjp.55.177. PMID 2041225.
  3. ↑ Gabryel B, Pudełko A, Trzeciak HI, Cieślik P (2000). "Effect of nebracetam on content of high-energy phosphates and morphometry of rat astrocytes in vitro. Comparison with piracetam". Acta Poloniae Pharmaceutica. 57 (4): 289–298. PMID 11126618.
  4. ↑ Yamashita S, Mase N, Takabe K (2008-09-22). "Chemoenzymatic total synthesis and determination of the absolute configuration of (S)-nebracetam". Tetrahedron: Asymmetry. 19 (18): 2115–2118. doi:10.1016/j.tetasy.2008.09.004. ISSN 0957-4166.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Nebracetam&oldid=1329595517"